Key result
Paper reviews Brugada syndrome background but reports no clinical outcomes for epicardial mapping and ablation.
Why the study?
The ECG manifestations of Brugada syndrome are often dynamic or concealed and may be unmasked or modulated by sodium channel blockers and other factors.
Brugada syndrome (BrS) is characterized by ST-segment elevation in right precordial leads on 12-lead electrocardiogram (ECG) with associated sudden cardiac death because of ventricular fibrillation (VF).1 The ECG manifestations of this syndrome are often dynamic or concealed and may be unmasked or modulated by sodium channel blockers, febrile state, vagotonic agents, α-adrenergic agonists, β-adrenergic blockers, a combination of glucose and insulin, hypo- and hyperkalemia, alcohol or cocaine toxicity, and tricyclic antidepressants, as well as other medical drugs.
No takes yet. Share an insight, caveat, or question.
González‐Melchor et al. (2015) studied Brugada syndrome. Epicardial mapping and ablation during flecainide testing was evaluated. The abstract provides background on Brugada syndrome but reports no clinical findings or outcomes for epicardial mapping and ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: